Malignant lymphomas; Hodgkin's disease; lymphocytic lymphoma; Burkitt's lymphoma; multiple myeloma; leukemias; advanced mycosis fungoides; disseminated neuroblastoma; enocarcinoma of the ovary; retinoblastoma; carcinoma of the breast; biopsy proven "minimal change" nephrotic syndrome in children.
Intravenously: 40-50 mg/kg in divided doses over a period of 2-5 days or IV 10-15 mg/kg given every 7-10 days or 3 -5 mg/kg twice weekly. Orally: 1-5 mg/kg/day for both initial and maintenance dosing. These are doses for oncolytic drug therapy for patients with no hematologic deficiency.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
An alkylating agent that interferes with DNA replication and transcription of RNA
It must be used only under constant supervision by physicians experienced in therapy with cytotoxic agents due to its low therapeutic index
Chronic myelogenous leukemia resistant to prior therapy with the drug
Nausea and vomiting [common side effect]; leukopenia; anaemia; thrombocytopenia; hyperuricaemia due to increased catabolism; uric acid nephropathy; renal stones; acute renal failure; increased chances of infection; alopecia [common particularly with this drug]; skin rash; pigmentation of the skin; changes in nails; cystitis; urinary bladder fibrosis; hemorrhagic ureteritis; renal tubular necrosis.